Praxis Precision Medicines, Inc. 8-K

What Happened
Praxis Precision Medicines, Inc. announced in an 8-K filed July 2, 2026 that its Audit Committee approved the dismissal of Ernst & Young LLP (EY) as the company's independent registered public accounting firm, effective June 29, 2026, and concurrently approved the engagement of KPMG LLP as the new independent auditor. EY’s audit reports for the fiscal years ended December 31, 2025 and December 31, 2024 were unqualified (no adverse opinion or disclaimer), and the company states there were no disagreements or reportable events with EY through June 29, 2026.

Key Details

• Dismissal and engagement effective date: June 29, 2026.
• Prior auditor: Ernst & Young LLP (EY); New auditor: KPMG LLP.
• EY’s reports for fiscal years ended Dec 31, 2025 and Dec 31, 2024 were not qualified or modified and contained no adverse opinion or disclaimer.
• The company reports no disagreements or reportable events with EY for the periods noted, and requested EY provide a letter to the SEC; that letter is filed as Exhibit 16.1. Praxis also disclosed it had not consulted KPMG on accounting or audit issues for the years ended Dec 31, 2025 and Dec 31, 2024 through June 29, 2026.

Why It Matters
A change in independent auditor is a notable governance event for investors because it affects who reviews and attests to the company’s financial statements. In this case, Praxis reports a routine transition—EY’s prior opinions were unqualified and there were no disagreements—reducing immediate concern about prior financial reporting. Investors should watch for any future disclosures about audit fees, transitional costs, or changes in audit scope once KPMG begins auditing upcoming periods.